Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections

Bibliography

• Allen NE. Macrolide resistance in Staphylococcus aureus: inducers of macrolide resistance. Antimicrob Agents Chemother 1977;11:669-74
   PubMedGoogle Scholar
• Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001;48(Suppl T1):1-8
   PubMed Web of Science ®Google Scholar
• Wilson DN, Harms JM, Nierhaus KH, et al. Species-specific antibiotic–ribosome interactions: implications for drug development. Biol Chem 2005;386:1239-52
   PubMed Web of Science ®Google Scholar
• Nilius AM, Ma Z. Ketolides: the future of the macrolides? Curr Opin Pharmacol 2002;2:493-500
   PubMed Web of Science ®Google Scholar
• Canton R, Mazzariol A, Morosini MI, et al. Telithromycin activity is reduced by efflux in Streptococcus pyogenes. J Antimicrob Chemother 2005;55:489-95
   PubMed Web of Science ®Google Scholar
• Ma Z, Nemoto PA. Discovery and development of ketolides as a new generation of macrolide antimicrobial agents. Curr Med Chem Anti infective Agents 2002;1:15-34
   Google Scholar
• Zhanel GG, Neuhauser MN. Ketolides (telithromycin, cethromycin). In: Yu VL, Edwards G, McKinnon PS, et al., editors. Antimicrobial Therapy and Vaccines. Volume II: Antimicrobial Agents. Esun Technologies, LLC; 2005. p. 201-21
   Google Scholar
• Bryskier A. New research in macrolides and ketolides since 1997. Expert Opin Investig Drugs 1999;8:1171-94
   PubMedGoogle Scholar
• Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661-9
   PubMed Web of Science ®Google Scholar
• Agouridas C, Bonnefoy A, Chantot JF. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob Agents Chemother 1997;41:2149-58
   PubMedGoogle Scholar
• Heggelund A, Undheim K. Preparation of cyclic 2′,3′-carbamate derivatives of erythromycin macrolide antibiotics. Bioorg Med Chem 2007;15:3266-77
   PubMed Web of Science ®Google Scholar
• Denis A, Agouridas C, Auger JM, et al. Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg Med Chem Lett 1999;9:3075-80
   PubMed Web of Science ®Google Scholar
• Zhu B, Marinelli BA, Abbanat D, et al. Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives. Bioorg Med Chem Lett 2006;16:1054-9
   PubMedGoogle Scholar
• Zhu B, Marinelli BA, Abbanat D, et al. Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives. Bioorg Med Chem Lett 2007;17:3900-4
   PubMed Web of Science ®Google Scholar
• Tennakoon MA, Henninger TC, Abbanat D, et al. Synthesis and antibacterial activity of C6-carbazate ketolides. Bioorg Med Chem Lett 2006;16:6231-5
   PubMed Web of Science ®Google Scholar
• Grant EB, Guiadeen D, Abbanat D, et al. Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides. Bioorg Med Chem Lett 2006;16:1929-33
   PubMedGoogle Scholar
• Agouridas C, Denis A, Auger JM, et al. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J Med Chem 1998;41:4080-100
   PubMed Web of Science ®Google Scholar
• Henninger TC, Xu X, Abbanat D, et al. Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics. Bioorg Med Chem Lett 2004;14:4495-9
   PubMed Web of Science ®Google Scholar
• Ma Z, Clark RF, Brazzale A, et al. Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J Med Chem 2001;44:4137-56
   PubMedGoogle Scholar
• Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs R&D 2007;8:95-102
   PubMedGoogle Scholar
• Revill P, Bolos J, Serradelli J. EDP-420: ketolide antibiotic. Drugs Future 2006;31:479-83
   Web of Science ®Google Scholar
• Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989;33:1413-8
   PubMed Web of Science ®Google Scholar
• Nagai K, Davies TA, Ednie LM, et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob Agents Chemother 2001;45:3242-5
   PubMed Web of Science ®Google Scholar
• Abbanat D, Webb G, Foleno B, et al. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides. Antimicrob Agents Chemother 2005;49:309-15
   PubMedGoogle Scholar
• Guitton M, Delachaume C, Le Priol P, et al. In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci. J Antimicrob Chemother 2001;48:131-5
   PubMedGoogle Scholar
• Nomura T, Yasukata T, Narukawa Y, et al. 9-Oxime-3-ketolides: modification at the C-11,12-diol moiety and antibacterial activities against key respiratory pathogens. Bioorg Med Chem 2005;13:6054-63
   PubMedGoogle Scholar
• Nomura T, Iwaki T, Narukawa Y, et al. A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: synthesis and structure–activity relationships. Bioorg Med Chem 2006;14:3697-711
   PubMed Web of Science ®Google Scholar
• Nomura T, Iwaki T, Yasukata T, et al. A new type of ketolides bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether synthesis and structure–activity relationships. Bioorg Med Chem 2005;13:6615-28
   PubMed Web of Science ®Google Scholar
• Burger MT, Lin X, Chu DT, et al. Synthesis and antibacterial activity of novel C12 vinyl ketolides. J Med Chem 2006;49:1730-43
   PubMed Web of Science ®Google Scholar
• Burger MT, Hiebert C, Seid M, et al. Synthesis and antibacterial activity of novel C12 ethyl ketolides. Bioorg Med Chem 2006;14:5592-604
   PubMed Web of Science ®Google Scholar
• Istuk ZM, Mutak S, Kujundzic N, et al. Novel 9a-carbamoyl- and 9a-thiocarbamoyl-3-decladinosyl-6-hydroxy and 6-methoxy derivatives of 15-membered macrolides. Bioorg Med Chem 2007;15:4498-510
   PubMedGoogle Scholar
• Ono T, Kashimura M, Suzuki K, et al. In vitro and in vivo antibacterial activities of the tricyclic ketolide TE-802 and its analogs. J Antibiot (Tokyo) 2004;57:518-27
   PubMedGoogle Scholar
• Morosini MI, Canton R, Loza E, et al. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 2003;52:50-5
   PubMed Web of Science ®Google Scholar
• Shortridge VD, Zhong P, Cao Z, et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002;46:783-6
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Roblin PM, Bebear CM. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 2001;48(Suppl T1):25-31
   PubMedGoogle Scholar
• Felmingham D, Farrell DJ. In vitro activity of telithromycin against Gram-negative bacterial pathogens. J Infect 2006;52:178-80
   PubMedGoogle Scholar
• Stout JE, Sens K, Mietzner S, et al. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005;25:302-7
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Higa F, Edelstein MA. In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:2685-90
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999;43:90-5
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Shackcloth J, Barbadora KA, et al. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother 2006;50:817-8
   PubMedGoogle Scholar
• Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 2007;45:290-3
   PubMed Web of Science ®Google Scholar
• Doern GV. Macrolide and ketolide resistance with Streptococcus pneumoniae. Med Clin North Am 2006;90:1109-24
   PubMed Web of Science ®Google Scholar
• Douthwaite S, Jalava J, Jakobsen L. Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol Microbiol 2005;58:613-22
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Felmingham D. The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 2005;56:795-7
   PubMedGoogle Scholar
• Rantala M, Haanpera-Heikkinen M, Lindgren M, et al. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 2006;50:1855-8
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Teng LJ, Wu TL, et al. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003;47:2145-51
   PubMedGoogle Scholar
• Malhotra-Kumar S, Lammens C, Chapelle S, et al. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999 – 2003. Emerg Infect Dis 2005;11:939-42
   PubMed Web of Science ®Google Scholar
• Grivea IN, Al Lahham A, Katopodis GD, et al. Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis. Antimicrob Agents Chemother 2006;50:256-61
   PubMed Web of Science ®Google Scholar
• Wolter N, Smith AM, Low DE, et al. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51:1092-5
   PubMed Web of Science ®Google Scholar
• Al Lahham A, Appelbaum PC, van der LM, et al. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe. Antimicrob Agents Chemother 2006;50:3897-900
   PubMedGoogle Scholar
• Hirakata Y, Mizuta Y, Wada A, et al. The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4. Jpn J Infect Dis 2007;60:48-50
   PubMed Web of Science ®Google Scholar
• Hisanaga T, Hoban DJ, Zhanel GG. Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 2005;56:447-50
   PubMed Web of Science ®Google Scholar
• Berisio R, Corti N, Pfister P, et al. 23S rRNA 2058A-->G alteration mediates ketolide resistance in combination with deletion in L22. Antimicrob Agents Chemother 2006;50:3816-23
   PubMed Web of Science ®Google Scholar
• Canu A, Malbruny B, Coquemont M, et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:125-31
   PubMed Web of Science ®Google Scholar
• Walsh F, Willcock J, Amyes S. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 2003;52:345-53
   PubMedGoogle Scholar
• Xiong L, Shah S, Mauvais P, et al. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol Microbiol 1999;31:633-9
   PubMed Web of Science ®Google Scholar
• Reinert RR, van der LM, Al Lahham A. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Antimicrob Agents Chemother 2005;49:3520-2
   PubMedGoogle Scholar
• Bogdanovich T, Bozdogan B, Appelbaum PC. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. Antimicrob Agents Chemother 2006;50:893-8
   PubMed Web of Science ®Google Scholar
• Reynolds ED, Cove JH. Resistance to telithromycin is conferred by msr(A), msrC and msr(D) in Staphylococcus aureus. J Antimicrob Chemother 2005;56:1179-80
   PubMed Web of Science ®Google Scholar
• Kerr ID, Reynolds ED, Cove JH. ABC proteins and antibiotic drug resistance: is it all about transport? Biochem Soc Trans 2005;33:1000-2
   PubMedGoogle Scholar
• Chesneau O, Tsvetkova K, Courvalin P. Resistance phenotypes conferred by macrolide phosphotransferases. FEMS Microbiol Lett 2007;269:317-22
   PubMed Web of Science ®Google Scholar
• Carryn S, Chanteux H, Seral C, et al. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 2003;17:615-34
   PubMed Web of Science ®Google Scholar
• Vazifeh D, Bryskier A, Labro MT. Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2000;44:511-21
   PubMed Web of Science ®Google Scholar
• Vazifeh D, Preira A, Bryskier A, et al. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998;42:1944-51
   PubMed Web of Science ®Google Scholar
• Bosnar M, Kelneric Z, Munic V, et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005;49:2372-7
   PubMed Web of Science ®Google Scholar
• Labro MT, Abdelghaffar H, Babin-Chevaye C. Interaction of the new ketolide ABT-773 (cethromycin) with human polymorphonuclear neutrophils and the phagocytic cell line PLB-985 in vitro. Antimicrob Agents Chemother 2004;48:1096-104
   PubMed Web of Science ®Google Scholar
• Seral C, Michot JM, Chanteux H, et al. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother 2003;47:1047-51
   PubMed Web of Science ®Google Scholar
• Seral C, Carryn S, Tulkens PM, et al. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 2003;51:1167-73
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Zhao YL, Nadai M, et al. Involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006;50:80-7
   PubMed Web of Science ®Google Scholar
• Kuehnel TS, Schurr C, Lotter K, et al. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chemother 2005;55:591-4
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Understanding pharmacokinetics and pharmacodynamics: application to the antimicrobial formulary decision process. In: Antibiotic Optimization – Concepts and Strategies in Clinical Practice. Owens RC, Ambrose PG, Nightingale CH, editors. Marcel Decker; 2005. p. 65-88
   Google Scholar
• Tessier PR, Mattoes HM, Dandekar PK, et al. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2005;49:188-94
   PubMed Web of Science ®Google Scholar
• Azoulay-Dupuis E, Mohler J, Bedos JP, et al. Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model. Antimicrob Agents Chemother 2006;50:3033-8
   PubMed Web of Science ®Google Scholar
• Barcia-Macay M, Seral C, Mingeot-Leclercq MP, et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006;50:841-51
   PubMed Web of Science ®Google Scholar
• Lodise TP, Preston S, Bhargava V, et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 2005;52:45-52
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Johanson C, Laing N, et al. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother 2005;49:1943-8
   PubMed Web of Science ®Google Scholar
• Shi J, Pfister M, Jenkins SG, et al. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia. Clin Pharmacokinet 2005;44:317-29
   PubMed Web of Science ®Google Scholar
• Macrolides, lincosamides, streptogramins – EUCAST clinical MIC breakpoints. EUCAST, 14-5-2007. Available from: http://www.srga.org/eucastwt/consultation/MICmacrolides.html [Last accessed: 6 November 2007]
   Google Scholar
• Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44:915-34
   PubMed Web of Science ®Google Scholar
• Ciervo CA, Shi J. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. Curr Med Res Opin 2005;21:1641-50
   PubMed Web of Science ®Google Scholar
• Reed M, Wall GC, Shah NP, et al. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother 2005;39:357-60
   PubMed Web of Science ®Google Scholar
• Nenciu LM, Laberge P, Thirion DJ. Telithromycin-induced digoxin toxicity and electrocardiographic changes. Pharmacotherapy 2006;26:872-6
   PubMedGoogle Scholar
• Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005;40:1657-64
   PubMed Web of Science ®Google Scholar
• Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35:779-86
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis-US, 2007. Available from: http://products.sanofi-aventis.us/ketek/Ketek.pdf Ketek. [Last accessed: 6 November 2007]
   Google Scholar
• Telithromycin (marketed as Ketek) Information. FDA, 2007. Available from: http://www.fda.gov/cder/drug/infopage/telithromycin/default.htm [Last accessed: 6 November 2007]
   Google Scholar
• Niederman MS. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005;26(Suppl 3):S170-5
   PubMedGoogle Scholar
• Das B, Sarkar C, Majumder AG. Medication use for pediatric upper respiratory tract infections. Fundam Clin Pharmacol 2006;20:385-90
   PubMed Web of Science ®Google Scholar
• MacDougall C, Guglielmo BJ, Maselli J, et al. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 2005;11:380-4
   PubMed Web of Science ®Google Scholar
• Poole MD. A focus on acute sinusitis in adults: changes in disease management. Am J Med 1999;106:38S-47S
   Google Scholar
• Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med 2001;134:509-17
   PubMed Web of Science ®Google Scholar
• Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805
   PubMed Web of Science ®Google Scholar
• Huchon GJ, Vergnenegre A, Neukirch F, et al. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002;20:806-12
   PubMedGoogle Scholar
• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
   PubMed Web of Science ®Google Scholar
• Donowitz GR, Mandell GL. Acute pneumonia. In: Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R, editors. Elsevier, Churchill Livingstone; 2005. p. 819-45
   Google Scholar
• Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther 2006;4:973-80
   PubMedGoogle Scholar
• Van Bambeke F, Reinert RR, Appelbaum PC, et al. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007;67:2355-82
   PubMedGoogle Scholar
• Norrby SR, Quinn J, Rangaraju M, et al. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis. Clin Microbiol Infect 2004;10:615-23
   PubMedGoogle Scholar
• Norrby SR, Rabie WJ, Bacart P, et al. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis 2001;33:883-90
   PubMedGoogle Scholar
• Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther 2003;25:422-43
   PubMed Web of Science ®Google Scholar
• Brook I, Hausfeld JN. Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis. Arch Otolaryngol Head Neck Surg 2006;132:442-5
   PubMedGoogle Scholar
• Carbon C. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. Infection 2003;31:308-17
   PubMedGoogle Scholar
• Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003;17:369-77
   PubMedGoogle Scholar
• Luterman M, Tellier G, Lasko B, et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003;82:576-4, 586
   PubMedGoogle Scholar
• Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002;48:100-8
   PubMed Web of Science ®Google Scholar
• Roos K, Tellier G, Baz M, et al. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect 2005;50:210-20
   PubMed Web of Science ®Google Scholar
• Tran MP. Telithromycin: a novel agent for the treatment of community-acquired upper respiratory infections. Proc (Bayl Univ Med Cent) 2004;17:475-9
   PubMedGoogle Scholar
• Ferguson BJ, Guzzetta RV, Spector SL, et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;131:207-14
   PubMed Web of Science ®Google Scholar
• Marple BF, Brunton S, Ferguson BJ. Acute bacterial rhinosinusitis: a review of US treatment guidelines. Otolaryngol Head Neck Surg 2006;135:341-8
   PubMedGoogle Scholar
• Anon JB. Current management of acute bacterial rhinosinusitis and the role of moxifloxacin. Clin Infect Dis 2005;41(Suppl 2):S167-76
   PubMedGoogle Scholar
• Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002;96:862-71
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003;31:157-69
   PubMed Web of Science ®Google Scholar
• Fogarty C, de Wet R, Mandell L, et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005;128:1980-8
   PubMed Web of Science ®Google Scholar
• Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600
   PubMed Web of Science ®Google Scholar
• Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21
   PubMed Web of Science ®Google Scholar
• Ferrara G, Losi M, Franco F, et al. Macrolides in the treatment of asthma and cystic fibrosis. Respir Med 2005;99:1-10
   PubMed Web of Science ®Google Scholar
• Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62
   PubMed Web of Science ®Google Scholar
• Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378-86
   PubMed Web of Science ®Google Scholar
• Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003;57:377-84
   PubMed Web of Science ®Google Scholar
• Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
   PubMed Web of Science ®Google Scholar
• van Rensburg DJ, Fogarty C, Kohno S, et al. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin. Chemotherapy 2005;51:186-92
   PubMedGoogle Scholar
• Fogarty CM, Patel TC, Dunbar LM, et al. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infect Dis 2005;5:43
   PubMedGoogle Scholar
• Carbon C, Moola S, Velancsics I, et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 2003;9:691-703
   PubMed Web of Science ®Google Scholar
• Carbon C, van Rensburg D, Hagberg L, et al. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. Respir Med 2006;100:577-85
   PubMedGoogle Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
   PubMed Web of Science ®Google Scholar
• Bearden DT, Neuhauser MM, Garey KW. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 2001;21:1204-22
   PubMed Web of Science ®Google Scholar
• Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006;144:415-20
   PubMed Web of Science ®Google Scholar
• EMEA statement on the safety of Ketek (telithromycin). European Medicine Agency, 27-1-2006. Available from: www.emea.europa.eu/pdfs/human/press/pr/2938606en.pdf [Last accessed: 6 November 2007]
   Google Scholar
• Soreth J, Cox E, Kweder S, et al. Ketek – the FDA perspective. N Engl J Med 2007;356:1675-6
   PubMed Web of Science ®Google Scholar
• Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-4
   PubMed Web of Science ®Google Scholar
• Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006;67:2256-8
   PubMedGoogle Scholar
• Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-9
   PubMed Web of Science ®Google Scholar
• Goossens H, Ferech M, Vander SR, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87
   PubMed Web of Science ®Google Scholar
• Coenen S, Ferech M, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 2006;58:418-22
   PubMedGoogle Scholar
• Goossens H, Ferech M, Coenen S, et al. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007;44:1091-5
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Michot JM, Van Eldere J, et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80
   PubMedGoogle Scholar
• Phan LT, Polemeropoulos A, Wang G, et al. In vitro antibacterial activity of EDP-420, a new bridged bicyclic macrolide, against US clinical isolates. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 2006;E-1858
   Google Scholar
• Jorgensen JH, Crawford SA, McElmeel ML, et al. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:605-7
   PubMed Web of Science ®Google Scholar
• Schmitz FJ, Schwarz S, Milatovic D, et al. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 2002;50:145-8
   PubMedGoogle Scholar
• Giovanetti E, Montanari MP, Marchetti F, et al. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. J Antimicrob Chemother 2000;46:905-8
   PubMed Web of Science ®Google Scholar
• Waites KB, Crabb DM, Duffy LB. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob Agents Chemother 2003;47:39-42
   PubMed Web of Science ®Google Scholar
• Yamano Y, Fujimura T, Maki H, et al. In vitro antibacterial activity of S-013420, a nex bridged bicyclic macrolide. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; 2006;E-1857
   Google Scholar
• Khair OA, Andrews JM, Honeybourne D, et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001;47:837-40
   PubMed Web of Science ®Google Scholar
• Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001;45:3104-8
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kipps J, et al. Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin. Antimicrob Agents Chemother 2004;48:3508-15
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Backman JT, et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther 2006;79:231-42
   PubMed Web of Science ®Google Scholar
• Antibiotics bound to the 50S subunit. Harms's and Schlunzen's riboworld, 2007. Available from: http://www.riboworld.com/antib/50santib-eng.shtml [Last accessed: 6 November 2007]
   Google Scholar
• Berisio R, Harms J, Schluenzen F, et al. Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol 2003;185:4276-9
   PubMedGoogle Scholar
• Tu D, Blaha G, Moore PB, et al. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 2005;121:257-70
   PubMed Web of Science ®Google Scholar
• Cannone JJ, Subramanian S, Schnare MN, et al. The comparative RNA web (CRW) site: an online database of comparative sequence and structure information for ribosomal, intron, and other RNAs. BMC Bioinformatics 2002;3:2
   PubMed Web of Science ®Google Scholar
• Douthwaite S. Structure–activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 2001;7(Suppl 3):11-7
   PubMed Web of Science ®Google Scholar